ARTICLE | Company News
BioXpress, AET BioTech to co-develop adalimumab biosimilar
October 31, 2012 12:35 AM UTC
BioXpress Therapeutics S.A. (Plan-les-Ouates, Switzerland) and AET BioTech partnered to co-develop a biosimilar version of autoimmune drug adalimumab, a human mAb against tumor necrosis factor (TNF) alpha. AET BioTech will provide "committed long term" funding and will be responsible for commercialization. The partners said the development strategy for the biosimilar "incorporates regulatory requirements for marketing in countries worldwide." Neither company could be reached for details. ...